open access

Online first
Short communication
Published online: 2021-11-16
Get Citation

Effect of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: sub-analysis of a prospective, observational study during COVID-19 pandemic

Dimitrios Patoulias1, Christodoulos Papadopoulos2, Ioanna Zografou1, Alexandra Katsimardou1, Konstantinos Imprialos1, Konstantinos Stavropoulos1, Antigoni Tranidou1, Asterios Karagiannis1, Michael Doumas13
DOI: 10.33963/KP.a2021.0160
·
Pubmed: 34783355
Affiliations
  1. 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece
  2. 3rd Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece
  3. Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia, United States of America

open access

Online first
Short communication
Published online: 2021-11-16

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Effect of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: sub-analysis of a prospective, observational study during COVID-19 pandemic

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Short communication

Published online

2021-11-16

DOI

10.33963/KP.a2021.0160

Pubmed

34783355

Authors

Dimitrios Patoulias
Christodoulos Papadopoulos
Ioanna Zografou
Alexandra Katsimardou
Konstantinos Imprialos
Konstantinos Stavropoulos
Antigoni Tranidou
Asterios Karagiannis
Michael Doumas

References (15)
  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016; 387(10027): 1513–1530.
  2. Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015; 372(14): 1333–1341.
  3. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43(2): 487–493.
  4. Sarafidis P, Ortiz A, Ferro CJ, et al. Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens. 2021; 39(6): 1090–1097.
  5. Packer M, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396(10254): 819–829.
  6. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12): 761–772.
  7. Ling HZ, Flint J, Damgaard M, et al. Calculated plasma volume status and prognosis in chronic heart failure. Eur J Heart Fail. 2015; 17(1): 35–43.
  8. Dekkers CCJ, Sjöström CD, Greasley PJ, et al. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019; 21(12): 2667–2673.
  9. Hoshika Yu, Kubota Y, Mozawa K, et al. Effect of empagliflozin versus placebo on plasma volume status in patients with acute myocardial infarction and type 2 diabetes mellitus. Diabetes Ther. 2021; 12(8): 2241–2248.
  10. Jensen J, Omar M, Kistorp C, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2021; 9(2): 106–116.
  11. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014; 16(11): 1087–1095.
  12. Matsubayashi Y, Yoshida A, Suganami H, et al. Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes Obes Metab. 2021; 23(7): 1660–1665.
  13. Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018; 20(3): 479–487.
  14. Ohara K, Masuda T, Murakami T, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan. Nephrology (Carlton). 2019; 24(9): 904–911.
  15. Patoulias D, Papadopoulos C, Kassimis G, et al. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Kardiol Pol. 2021; 79(9): 1048–1049.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl